Log In
Print
BCIQ
Print
Print this Print this
 

Glucovance, metformin/glyburide

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionGlyburide sulfonylurea plus metformin oral agent that improves glucose tolerance
Molecular Target ATP-dependent potassium channel (KATP)
Mechanism of ActionATP-dependent potassium channel (KATP) blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today